The CFO & EVP of Ultragenyx Pharmaceutical is Exercising Options

By Carrie Williams

Yesterday it was reported that the CFO & EVP of Ultragenyx Pharmaceutical (RAREResearch Report), Shalini Sharp, exercised options to sell 14,378 RARE shares at $61.50 a share, for a total transaction value of $1.27M.

Following Shalini Sharp’s last RARE Sell transaction on June 05, 2020, the stock climbed by 18.0%. In addition to Shalini Sharp, 2 other RARE executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ultragenyx Pharmaceutical’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $36.31 million and GAAP net loss of -$119,025,000. In comparison, last year the company earned revenue of $24.15 million and had a GAAP net loss of $99.17 million. The company has a one-year high of $91.77 and a one-year low of $31.99. Currently, Ultragenyx Pharmaceutical has an average volume of 89.54K.

Based on 11 analyst ratings, the analyst consensus is Strong Buy with an average price target of $87.18, reflecting a -0.1% downside.

The insider sentiment on Ultragenyx Pharmaceutical has been negative according to 94 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Shalini Sharp’s trades have generated a -5.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.